Clinical Trial Update: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of the oral agent SHR0302 in subjects aged 12 years and older with moderate to severe atopic dermatiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SHR0302 (SHR0302)

Snippet

Sponsor: Reistone Biopharma Company Limited | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED